ArticleThe Journal of infection2021
Serum cholinesterase associated with COVID-19 pneumonia severity and mortality.
Abstract readLetterComment
In one paragraph
Article in The Journal of infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Butyrylcholinesterase Activity as a Mortality Marker in ICU Patients: An Individual Participant Data Meta-Analysis.Critical care explorations · 2026Pooled it
- Measurement of acetylcholinesterase activity by electrochemical analysis method utilizing organocatalytic reactions.RSC advances · 2025Article
- Variation in Gene Expression Across Infection Status and Elevation in a Hawaiian Honeycreeper.Ecology and evolution · 2025Article
- Serum butyrylcholinesterase activity as a predictor of severity and mortality in COVID-19 patients.Scientific reports · 2025Article
- Butyrylcholinesterase and 24 h-urinary copper excretion as compliance assessment in long-term treated Wilson's disease.Frontiers in neurology · 2025Article
- The association between preoperative serum cholinesterase and all-cause mortality in geriatric patients with hip fractures: a cohort study of 2387 patients.Perioperative medicine (London, England) · 2024Article
- Article
- The Potential Risk of Reduced Serum Cholinesterase Activity in COVID-19 Patients Suffering From Cytokine Storm.Cureus · 2024Article
- Cholinesterase activities and sepsis-associated encephalopathy in viral versus nonviral sepsis.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2024Article
- Use of the Serum Level of Cholinesterase as a Prognostic Marker of Nonfatal Clinical Outcomes in Patients Hospitalized with Acute Exacerbations of Chronic Obstructive Pulmonary Disease.Canadian respiratory journal · 2024Article
- Serum butyrylcholinesterase as a marker of COVID-19 mortality: Results of the monocentric prospective observational study.Chemico-biological interactions · 2023Observational
- Cholinergic dysfunction in COVID-19: frantic search and hoping for the best.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Toxin-like Peptides from the Bacterial Cultures Derived from Gut Microbiome Infected by SARS-CoV-2-New Data for a Possible Role in the Long COVID Pattern.Biomedicines · 2022Article
- Pseudocholinesterase as a Biomarker for Untreated Wilson's Disease.Biomolecules · 2022Article
- Cholinesterase Deficiency Syndrome-A Pitfall in the Use of Butyrylcholinesterase as a Biomarker for Wilson's Disease.Biomolecules · 2022Article
- Critically Ill COVID-19 Patients Show Reduced Point of Care-Measured Butyrylcholinesterase Activity-A Prospective, Monocentric Observational Study.Diagnostics (Basel, Switzerland) · 2022Article
- Clinical characteristics and outcomes of critically ill COVID-19 patients in Sfax, Tunisia.Acute and critical care · 2022Article
- Does serum butyrylcholinesterase level determine the severity and mortality of COVID-19 pneumonia?: Prospective study.Frontiers in medicine · 2022Article
- Severity predictors of COVID-19 in SARS-CoV-2 variant, delta and omicron period; single center study.PloS one · 2022Article
- Use of Tox21 Screening Data to Evaluate the COVID-19 Drug Candidates for Their Potential Toxic Effects and Related Pathways.Frontiers in pharmacology · 2022Review
Corrections and comments
- Comment on
Authors and funding
12 authors.
Kento NakajimaDepartment of Emergency Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan. Electronic address: kento@yokohama-cu.ac.jp.
Takeru AbeDepartment of Emergency Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
Ryo SajiDepartment of Emergency Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
Fumihiro OgawaDepartment of Emergency Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
Hayato TaniguchiDepartment of Emergency Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
Keishi YamaguchiDepartment of Emergency Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
Kazuya SakaiDepartment of Emergency Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
Tomoki NakagawaDepartment of Emergency Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
Reo MatsumuraDepartment of Emergency Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
Yasufumi OiDepartment of Emergency Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
Mototsugu NishiiDepartment of Emergency Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
Ichiro TakeuchiDepartment of Emergency Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19BiomarkersCholinesterasesHumansLiverSARS-CoV-2Severity of Illness IndexBiomarkersCholinesterases
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.